Advanced MR Imaging Techniques in the Evaluation of Nonenhancing Gliomas: Perfusion-Weighted Imaging Compared with Proton Magnetic Resonance Spectroscopy and Tumor Grade

Abstract

A significant number of nonenhancing (NE) gliomas are reported to be malignant. The purpose of this study was to compare the value of advanced MR imaging techniques, including T2*-dynamic susceptibility contrast PWI (DSC-PWI) and proton magnetic resonance spectroscopy (¹HMRS) in the evaluation of NE gliomas. Twenty patients with NE gliomas underwent MRI including DSC-PWI and ¹HMRS. The relative CBV (rCBV) measurements were obtained from regions of maximum perfusion. The peak ratios of choline/creatine (Cho/Cr) and myo-inositol/creatine (mIns/Cr) were measured at a TE of 30 ms. Demographic features, tumor volumes, and PWI- and ¹HMRS-derived measures were compared between low-grade gliomas (LGGs) and high-grade gliomas (HGGs). In addition, the association of initial rCBV ratio with tumor progression was evaluated in LGGs. No significant difference was noted in age, sex or tumor size between LGGs and HGGs. Cho/Cr ratios were significantly higher in HGGs (1.7±0.63) than in LGGs (1.2±0.38). The receiver operating characteristic analysis demonstrated that a Cho/Cr ratio with a cutoff value of 1.3 could differentiate between LGG and HGG with a specificity of 100% and a sensitivity of 71.4%. There was no significant difference in the rCBV ratio and the mIns/Cr ratio between LGG and HGG. However, higher rCBV ratios were observed with more rapid progressions in LGGs. The results imply that Cho/Cr ratios are useful in distinguishing NE LGG from HGG and can be helpful in preoperative grading and biopsy guidance. On the other hand, rCBV ratios do not help in the distinction.

Keywords

nonenhancing glioma MR spectroscopy perfusion MRI

Get full access to this article

View all access options for this article.

References

Kleihues

Cavenee

. Pathology and genetics of tumours of the nervous system. Lyon: International Agency for Research on Cancer; 2000.

Morita

Wang

Chawla

. Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas. J Magn Reson Imaging. 2010; 32 (4): 803–808.

Ginsberg

Fuller

Hashmi

. The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol. 1998; 49 (4): 436–440.

Al-Okaili

Krejza

Wang

. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics. 2006; 26 (Suppl 1): S173–189.

Maia

Jr Malheiros

da Rocha

. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. Am J Neuroradiol. 2005; 26 (4): 777–783.

Batra

Tripathi

Singh

. Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Australas Radiol. 2004; 48 (3): 324–332.

Cha

Knopp

Johnson

. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology. 2002; 223 (1): 11–29.

Rorden

Brett

. Stereotaxic display of brain lesions. Behav Neurol. 2000; 12 (4): 191–200.

Wetzel

Cha

Johnson

. Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. Radiology. 2002; 224 (3): 797–803.

10.

Govindaraju

Young

Maudsley

. Proton NMR chemical shifts and coupling constants for brain metabolites. NMR Biomed. 2000; 13 (3): 129–153.

11.

Lev

Ozsunar

Henson

. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. Am J Neuroradiol. 2004; 25 (2): 214–221.

12.

McKnight

Smith

Chu

. Choline metabolism, proliferation, and angiogenesis in nonenhancing grades 2 and 3 astrocytoma. J Magn Reson Imaging. 2011; 33 (4): 808–816.

13.

Liu

Tian

Kolar

. MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol. 2011; 13 (4): 447–455.

14.

Law

Yang

Wang

. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. Am J Neuroradiol. 2003; 24 (10): 1989–1998.

15.

Castillo

Kwock

. Proton MR spectroscopy of common brain tumors. Neuroimaging Clin N Am. 1998; 8 (4): 733–752.

16.

Fayed

Modrego

. The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumors. J Neurooncol. 2005; 72 (3): 261–265.

17.

Toyooka

Kimura

Uematsu

. Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation. Clin Imaging. 2008; 32 (4): 251–258.

18.

Cerdàn

Parrilla

Santoro

. 1H NMR detection of cerebral myo-inositol. FEBS Lett. 1985; 187 (1): 167–172.

19.

Danielsen

Ross

. Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: Marcel Decker; 1999. p 30–34.

20.

Castillo

Smith

Kwock

. Correlation of myo-inositol levels and grading of cerebral astrocytomas. Am J Neuroradiol. 2000; 21 (9): 1645–1649.

21.

Law

Babb

. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging - Prediction of patient clinical response. Radiology. 2006; 238 (2): 658–667.

22.

Danchaivijitr

Waldman

Tozer

. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008; 247 (1): 170–178.

23.

Law

Johnson

. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery. 2006; 58 (6): 1099–1107.

24.

Guillevin

Menuel

Abud

. Proton MR spectroscopy in predicting the increase of perfusion MR imaging for WHO grade II gliomas. J Magn Reson Imaging. 2012; 35 (3): 543–550.

25.

See

. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery. 2005; 56 (5): 919–926.

26.

Chawla

Oleaga

Wang

. Role of proton magnetic resonance spectroscopy in differentiating oligodendrogliomas from astrocytomas. J Neuroimaging. 2010; 20 (1): 3–8.